Daniel Grossman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8723145/publications.pdf

Version: 2024-02-01

147566 182168 3,369 116 31 51 citations h-index g-index papers 116 116 116 1812 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incidence of Emergency Department Visits and Complications After Abortion. Obstetrics and Gynecology, 2015, 125, 175-183.	1.2	190
2	Effectiveness and Acceptability of Medical Abortion Provided Through Telemedicine. Obstetrics and Gynecology, 2011, 118, 296-303.	1.2	128
3	Change in abortion services after implementation of a restrictive law in Texas. Contraception, 2014, 90, 496-501.	0.8	125
4	Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond. Contraception, 2020, 101, 361-366.	0.8	113
5	Complications after Second Trimester Surgical and Medical Abortion. Reproductive Health Matters, 2008, 16, 173-182.	1.3	99
6	Challenging unintended pregnancy as an indicator of reproductive autonomy. Contraception, 2019, 100, 1-4.	0.8	98
7	Safety of Medical Abortion Provided Through Telemedicine Compared With In Person. Obstetrics and Gynecology, 2017, 130, 778-782.	1.2	90
8	Women's experiences seeking abortion care shortly after the closure of clinics due to a restrictive law in Texas. Contraception, 2016, 93, 292-297.	0.8	85
9	Sixteen Years of Overregulation: Time to Unburden Mifeprex. New England Journal of Medicine, 2017, 376, 790-794.	13.9	85
10	Women's and Providers' Experiences with Medical Abortion Provided Through Telemedicine: A Qualitative Study. Women's Health Issues, 2013, 23, e117-e122.	0.9	81
11	Accuracy of Self-Screening for Contraindications to Combined Oral Contraceptive Use. Obstetrics and Gynecology, 2008, 112, 572-578.	1.2	80
12	Self-induction of abortion among women in the United States. Reproductive Health Matters, 2010, 18, 136-146.	1.3	79
13	Unmet demand for highly effective postpartum contraception in Texas. Contraception, 2014, 90, 488-495.	0.8	77
14	Integration of family planning services into HIV care and treatment in Kenya. Aids, 2013, 27, S77-S85.	1.0	72
15	Women's Perspectives on Medical Abortion in Mexico, Colombia, Ecuador and Peru: A Qualitative Study. Reproductive Health Matters, 2005, 13, 75-83.	1.3	65
16	Interest in over-the-counter access to oral contraceptives among women in the United States. Contraception, 2013, 88, 544-552.	0.8	62
17	Complications of Unsafe and Self-Managed Abortion. New England Journal of Medicine, 2020, 382, 1029-1040.	13.9	61
18	Continuation of Prescribed Compared With Over-the-Counter Oral Contraceptives. Obstetrics and Gynecology, 2011, 117, 551-557.	1.2	57

#	Article	IF	CITATIONS
19	Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception, 2013, 88, 91-96.	0.8	52
20	Prevalence of Self-Managed Abortion Among Women of Reproductive Age in the United States. JAMA Network Open, 2020, 3, e2029245.	2.8	50
21	Women's Experience Obtaining Abortion Care in Texas after Implementation of Restrictive Abortion Laws: A Qualitative Study. PLoS ONE, 2016, 11, e0165048.	1.1	45
22	Mifepristone by prescription: a dream in the United States but reality in Australia. Contraception, 2015, 92, 186-189.	0.8	44
23	Confronting the challenge of unsafe secondâ€trimester abortion. International Journal of Gynecology and Obstetrics, 2011, 115, 77-79.	1.0	43
24	Experiences Accessing Abortion Care in Alabama among Women Traveling for Services. Women's Health Issues, 2016, 26, 298-304.	0.9	42
25	Continuing pregnancy after mifepristone and "reversal―of first-trimester medical abortion: a systematic review. Contraception, 2015, 92, 206-211.	0.8	41
26	Clinic Versus Over-the-Counter Access to Oral Contraception: Choices Women Make Along the US–Mexico Border. American Journal of Public Health, 2010, 100, 1130-1136.	1.5	40
27	Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating and implementing a core outcome set for medical and surgical abortion. Contraception, 2017, 95, 437-441.	0.8	39
28	Pharmacist Intentions to Prescribe Hormonal Contraception Following New Legislative Authority in California. Journal of Pharmacy Practice, 2019, 32, 54-61.	0.5	38
29	The public health threat of anti-abortion legislation. Contraception, 2014, 89, 73-74.	0.8	37
30	Change in Second-Trimester Abortion After Implementation of a Restrictive State Law. Obstetrics and Gynecology, 2019, 133, 771-779.	1.2	37
31	Integration of family planning services into HIV care clinics: Results one year after a cluster randomized controlled trial in Kenya. PLoS ONE, 2017, 12, e0172992.	1.1	35
32	Induced Abortion Provision Among a National Sample of Obstetrician–Gynecologists. Obstetrics and Gynecology, 2019, 133, 477-483.	1.2	35
33	Surgical and medical second trimester abortion in South Africa: A cross-sectional study. BMC Health Services Research, 2011, 11, 224.	0.9	33
34	Mortality of induced abortion, other outpatient surgical procedures and common activities in the United States. Contraception, 2014, 90, 476-479.	0.8	31
35	Unintended pregnancy among active-duty women in the United States military, 2011. Contraception, 2015, 92, 589-595.	0.8	31
36	A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study. PLoS ONE, 2018, 13, e0189195.	1.1	30

#	Article	IF	Citations
37	Telemedicine provision of medical abortion in Alaska: Through the provider's lens. Journal of Telemedicine and Telecare, 2017, 23, 680-685.	1.4	29
38	Support for and interest in alternative models of medication abortion provision among a national probability sample of U.S. women. Contraception, 2019, 99, 118-124.	0.8	29
39	Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal. PLoS ONE, 2018, 13, e0191174.	1.1	28
40	Texas women's decisions and experiences regarding self-managed abortion. BMC Women's Health, 2020, 20, 6.	0.8	28
41	Changes in Abortion in Texas Following an Executive Order Ban During the Coronavirus Pandemic. JAMA - Journal of the American Medical Association, 2021, 325, 691.	3.8	27
42	Over-the-Counter Access to Oral Contraceptives for Adolescents. Journal of Adolescent Health, 2017, 60, 634-640.	1.2	26
43	Interest in Over-the-Counter Access to a Progestin-Only Pill among Women in the United States. Women's Health Issues, 2018, 28, 144-151.	0.9	26
44	Breaking down barriers to birth control access: An assessment of online platforms prescribing birth control in the USA. Journal of Telemedicine and Telecare, 2020, 26, 322-331.	1.4	26
45	The Impending Crisis of Access to Safe Abortion Care in the US. JAMA Internal Medicine, 2022, 182, 793.	2.6	26
46	Public funding for abortion where broadly legal. Contraception, 2016, 94, 453-460.	0.8	25
47	Telemedicine for Family Planning. Obstetrics and Gynecology Clinics of North America, 2020, 47, 287-316.	0.7	25
48	Delays and barriers to care in Colombia among women obtaining legal first―and secondâ€ŧrimester abortion. International Journal of Gynecology and Obstetrics, 2015, 131, 285-288.	1.0	24
49	Over-the-Counter Access to Oral Contraceptives. Obstetrics and Gynecology Clinics of North America, 2015, 42, 619-629.	0.7	24
50	Implementing best practices for the provision of long-acting reversible contraception: a survey of obstetrician-gynecologists. Contraception, 2019, 100, 123-127.	0.8	23
51	Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee. Contraception, 2019, 99, 265-266.	0.8	23
52	Accuracy of a semi-quantitative urine pregnancy test compared to serum beta-hCG measurement: a possible screening tool for ongoing pregnancy after medication abortion. Contraception, 2007, 76, 101-104.	0.8	22
53	Integrating family planning into HIV care in western Kenya: HIV care providers' perspectives and experiences one year following integration. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 209-213.	0.6	22
54	Women's Experiences Using Telemedicine to Attend Abortion Information Visits in Utah: A Qualitative Study. Women's Health Issues, 2019, 29, 407-413.	0.9	22

#	Article	IF	CITATIONS
55	Medication Abortion With Pharmacist Dispensing of Mifepristone. Obstetrics and Gynecology, 2021, 137, 613-622.	1.2	22
56	Self-induction of abortion among women accessing second-trimester abortion services in the public sector, Western Cape Province, South Africa: An exploratory study. South African Medical Journal, 2014, 104, 302.	0.2	21
57	Women's Knowledge of and Support for Abortion Restrictions in Texas: Findings from a Statewide Representative Survey. Perspectives on Sexual and Reproductive Health, 2016, 48, 189-197.	0.9	21
58	Reaching women where they are: eliminating the initial in-person medical abortion visit. Contraception, 2015, 92, 190-193.	0.8	20
59	Clinical Outcomes and Women's Experiences before and after the Introduction of Mifepristone into Second-Trimester Medical Abortion Services in South Africa. PLoS ONE, 2016, 11, e0161843.	1.1	20
60	Over-the-counter access to oral contraceptives. Expert Review of Obstetrics and Gynecology, 2011, 6, 501-508.	0.4	19
61	Over-the-counter access to oral contraceptives as a reproductive healthcare strategy. Current Opinion in Obstetrics and Gynecology, 2013, 25, 500-505.	0.9	19
62	Abortion "Reversal―â€" Legislating without Evidence. New England Journal of Medicine, 2018, 379, 1491-1493.	13.9	19
63	Accuracy of self-assessment of gestational duration among people seeking abortion. American Journal of Obstetrics and Gynecology, 2022, 226, 710.e1-710.e21.	0.7	19
64	A randomized trial of misoprostol versus laminaria before dilation and evacuation in South Africa. Contraception, 2014, 90, 234-241.	0.8	18
65	Barriers to abortion care and incidence of attempted self-managed abortion among individuals searching Google for abortion care: A national prospective study. Contraception, 2022, 106, 49-56.	0.8	18
66	Attitudes Toward Overâ€theâ€Counter Access To Oral Contraceptives Among a Sample Of Abortion Clients in the United States. Perspectives on Sexual and Reproductive Health, 2014, 46, 83-89.	0.9	17
67	Providing Family Planning Services at Primary Care Organizations after the Exclusion of Planned Parenthood from Publicly Funded Programs in Texas: Early Qualitative Evidence. Health Services Research, 2018, 53, 2770-2786.	1.0	17
68	Telemedicine for medication abortion. Contraception, 2019, 100, 351-353.	0.8	15
69	Characteristics of patients having telemedicine versus in-person informed consent visits before abortion in Utah. Contraception, 2020, 101, 56-61.	0.8	13
70	Border-state abortions increased for Texas residents after House Bill 2. Contraception, 2021, 104, 314-318.	0.8	13
71	Sexual and reproductive health under the Trump presidency: policy change threatens women in the USA and worldwide. Journal of Family Planning and Reproductive Health Care, 2017, 43, 89-91.	0.9	12
72	Disruptions to Abortion Care in Louisiana During Early Months of the COVID-19 Pandemic. American Journal of Public Health, 2021, 111, 1504-1512.	1.5	12

#	Article	IF	Citations
73	Perspectives among a Diverse Sample of Women on the Possibility of Obtaining Oral Contraceptives Over the Counter: AÂQualitative Study. Women's Health Issues, 2016, 26, 147-152.	0.9	11
74	An analysis of delays among women accessing second-trimester abortion in the public sector in South Africa. Contraception, 2019, 100, 209-213.	0.8	11
7 5	Introduction of telemedicine for medication abortion: Changes in service delivery patterns in two U.S. states. Contraception, 2021, 103, 151-156.	0.8	11
76	The Health Consequences of Restrictive Abortion Laws. JAMA Internal Medicine, 2021, 181, 713.	2.6	11
77	Impact of family planning health talks by lay health workers on contraceptive knowledge and attitudes among HIV-infected patients in rural Kenya. Patient Education and Counseling, 2014, 94, 438-441.	1.0	10
78	Experiences with pain of early medical abortion: qualitative results from Nepal, South Africa, and Vietnam. BMC Women's Health, 2019, 19, 118.	0.8	10
79	Contraception after medication abortion in the United States: results from a cluster randomized trial. American Journal of Obstetrics and Gynecology, 2018, 218, 107.e1-107.e8.	0.7	9
80	Rebound of medication abortion in Texas following updated mifepristone label. Contraception, 2019, 99, 278-280.	0.8	9
81	Obstetrician-gynecologist willingness to provide medication abortion with removal of the in-person dispensing requirement for mifepristone. Contraception, 2021, 104, 73-76.	0.8	9
82	Does Integrating Family Planning into HIV Services Improve Gender Equitable Attitudes? Results from a Cluster Randomized Trial in Nyanza, Kenya. AIDS and Behavior, 2016, 20, 1883-1892.	1.4	8
83	Pre-Abortion Informed Consent Through Telemedicine vs. in Person: Differences in Patient Demographics and Visit Satisfaction. Women's Health Issues, 2021, 31, 227-235.	0.9	8
84	The Use of Public Health Evidence in <i>Whole Woman's Health v Hellerstedt</i> . JAMA Internal Medicine, 2017, 177, 155.	2.6	7
85	Evaluating the capacity of California's publicly funded universities to provide medication abortion. Contraception, 2018, 98, 306-311.	0.8	7
86	Oral and IUD emergency contraception provision among a national sample of obstetrician–gynecologists. Contraception, 2020, 102, 406-408.	0.8	7
87	Standardizing abortion research outcomes (STAR): Results from an international consensus development study. Contraception, 2021, 104, 484-491.	0.8	7
88	Making the case for advance provision of mifepristone and misoprostol for abortion in the United States. BMJ Sexual and Reproductive Health, 2022, 48, 238-242.	0.9	7
89	Bringing evidence to the debate on abortion coverage in health reform legislation: findings from a national survey in the United States. Contraception, 2010, 82, 129-130.	0.8	6
90	Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days' gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial. Reproductive Health, 2016, 13, 132.	1.2	6

#	Article	IF	Citations
91	Does information about abortion safety affect Texas voters' opinions about restrictive laws? A randomized study. Contraception, 2017, 96, 381-387.	0.8	6
92	Doing more for less: identifying opportunities to expand public sector access to safe abortion in South Africa through budget impact analysis. Contraception, 2018, 97, 167-176.	0.8	6
93	Abortion Referral Practices among a National Sample of Obstetrician-Gynecologists. Women's Health Issues, 2020, 30, 446-452.	0.9	6
94	Contraceptive use and access among deployed US servicewomen: findings from an online survey. BMJ Sexual and Reproductive Health, 2021, 47, 61-66.	0.9	6
95	Two prophylactic pain management regimens for medical abortion â‰ g 3 days' gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception, 2021, 103, 163-170.	0.8	6
96	Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessment. Contraception, 2022, 107, 36-41.	0.8	6
97	Perspectives on self-managed abortion among providers in hospitals along the Texas–Mexico border. BMC Women's Health, 2021, 21, 132.	0.8	5
98	Exploring Attitudes About the Legality of Self-Managed Abortion in the US: Results from a Nationally Representative Survey. Sexuality Research and Social Policy, 2022, 19, 574-587.	1.4	5
99	Improving Assessment of Demand for Postpartum Tubal Ligation among Publicly Insured Women in Texas. Contraception, 2021, 104, 518-523.	0.8	5
100	An observational study of patient experiences with a direct-to-patient telehealth abortion model in Australia. BMJ Sexual and Reproductive Health, 2021, , bmjsrh-2021-201259.	0.9	5
101	Women's Perspectives on Age Restrictions for Over-the-Counter Access to Oral Contraceptives. Journal of Adolescent Health, 2015, 56, 38-43.	1.2	4
102	Expanding Access to Short-Acting Hormonal Contraceptive Methods in the United States. JAMA Internal Medicine, 2019, 179, 1209.	2.6	4
103	Could routine pregnancy self-testing facilitate earlier recognition of unintended pregnancy? A feasibility study among South African women. BMJ Sexual and Reproductive Health, 2021, , bmjsrh-2020-201017.	0.9	4
104	Comprehension of an Over-the-Counter Drug Facts Label Prototype for a Mifepristone and Misoprostol Medication Abortion Product. Obstetrics and Gynecology, 2022, 139, 1111-1122.	1.2	4
105	Acceptability and clinical outcomes of first- and second-trimester surgical abortion by suction aspiration in Colombia. Contraception, 2014, 90, 242-248.	0.8	3
106	Pregnancy and Abortion: Experiences and Attitudes of Deployed U.S. Servicewomen. Military Medicine, 2020, 185, e1390-e1390.	0.4	3
107	Modeling the Impacts of Price of an Over-the-Counter Progestin-Only Pill on Use and Unintended Pregnancy among U.S. Women. Women's Health Issues, 2020, 30, 153-160.	0.9	3
108	Mifepristone–misoprostol versus misoprostol-alone regimen for medication abortion at ≥24 weeks' gestation. Contraception, 2020, 102, 99-103.	0.8	3

#	Article	IF	CITATIONS
109	Immediate versus delayed insertion of the copper intrauterine device after medical abortion at 17–20 gestational weeks: a randomised controlled trial. BMJ Sexual and Reproductive Health, 2022, 48, 28-34.	0.9	3
110	Over-the-counter oral contraceptive use among women in Mexico: results from a national survey. BMJ Sexual and Reproductive Health, 2021, 47, 205-210.	0.9	3
111	A Randomized Study Evaluating the Effect of Evidence-Based Information on Clinician Attitudes About Moving Oral Contraceptives Over the Counter. Journal of Women's Health, 2021, 30, 1626-1636.	1.5	2
112	A cross-sectional survey of U.S. abortion patients' interest in obtaining medication abortion over the counter. Contraception, 2022, 109, 25-31.	0.8	2
113	Time from first clinical contact to abortion in Texas and California. Contraception, 2022, 110, 76-80.	0.8	1
114	Off-label indications for mifepristone in gynecology and obstetrics. Contraception, 2015, 92, 203-205.	0.8	0
115	Reply to: "mifepristone by prescription: not quite a reality in Australia― Contraception, 2016, 94, 379.	0.8	O
116	Miscarriage information available on the internet: a content analysis of leading consumer websites. Contraception: X, 2019, 1, 100010.	0.6	0